These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30649746)

  • 21. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
    Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
    Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plecanatide, Nusinersen, and Obeticholic acid.
    Hussar DA; Douglas DK
    J Am Pharm Assoc (2003); 2017; 57(3):416-418. PubMed ID: 28506401
    [No Abstract]   [Full Text] [Related]  

  • 23. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation.
    Rao SSC
    Therap Adv Gastroenterol; 2018; 11():1756284818777945. PubMed ID: 29942351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutically targeting guanylate cyclase-C: computational modeling of plecanatide, a uroguanylin analog.
    Brancale A; Shailubhai K; Ferla S; Ricci A; Bassetto M; Jacob GS
    Pharmacol Res Perspect; 2017 Apr; 5(2):e00295. PubMed ID: 28357122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide.
    Rao SSC; Laitman AP; Miner PB
    Clin Transl Gastroenterol; 2023 Jul; 14(7):e00598. PubMed ID: 37162147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examining linaclotide for the treatment of chronic idiopathic constipation.
    Taclob JA; Kalas MA; McCallum RW
    Expert Opin Pharmacother; 2024 Jul; 25(10):1281-1290. PubMed ID: 39058326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
    Sharma S; Sharma T; Dhingra R; Tomar P; Singh S; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Oct; 13(11):1685-90. PubMed ID: 24001336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
    Tse Y; Armstrong D; Andrews CN; Bitton A; Bressler B; Marshall J; Liu LW
    Can J Gastroenterol Hepatol; 2017; 2017():8612189. PubMed ID: 28271055
    [No Abstract]   [Full Text] [Related]  

  • 30. New pharmacological treatment options for irritable bowel syndrome with constipation.
    Nusrat S; Miner PB
    Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    Lasa JS; Altamirano MJ; Bracho LF; Paz S; Zubiaurre I
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):2-12. PubMed ID: 30088533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.
    Camilleri M
    Gastroenterology; 2015 Mar; 148(3):483-7. PubMed ID: 25576859
    [No Abstract]   [Full Text] [Related]  

  • 33. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.
    Shailubhai K; Comiskey S; Foss JA; Feng R; Barrow L; Comer GM; Jacob GS
    Dig Dis Sci; 2013 Sep; 58(9):2580-6. PubMed ID: 23625291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current developments in pharmacological therapeutics for chronic constipation.
    Jiang C; Xu Q; Wen X; Sun H
    Acta Pharm Sin B; 2015 Jul; 5(4):300-9. PubMed ID: 26579459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation.
    DeMicco M; Barrow L; Hickey B; Shailubhai K; Griffin P
    Therap Adv Gastroenterol; 2017 Nov; 10(11):837-851. PubMed ID: 29147135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expanded table: some drugs for chronic idiopathic constipation.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):e88-e90. PubMed ID: 31170121
    [No Abstract]   [Full Text] [Related]  

  • 37. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.
    Waldman SA; Camilleri M
    Gut; 2018 Aug; 67(8):1543-1552. PubMed ID: 29563144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New treatment targets for the management of irritable bowel syndrome.
    Rao S; Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relief for Chronic Constipation.
    Voelker R
    JAMA; 2017 Mar; 317(9):900. PubMed ID: 28267840
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.